Cancer Neuroscience: Innovative Conception and Emerging Strategy of Therapy

Abstract

Cancer neuroscience has emerged as a paradigm-shifting discipline that reveals the active role of the nervous system in tumor development and progression. This review synthesizes current understanding of how bidirectional interactions between neurons and cancer cells influence tumorigenesis, metastasis, and therapy response. While earlier frameworks have established the fundamental mechanisms of nerve–tumor interactions, the present study proposes an expanded classification scheme that incorporates two additional mechanisms: perineural invasion as a unique metastatic pathway and neuro-microbic-oncology, which incorporates the gut–brain–immune axis into cancer biology. The remodeling of tumor microenvironment is structured around three principal mechanisms: electrochemical signaling, paracrine communication, and neuroimmune modulation. The contribution of these interactions to cancer-associated comorbidities, including pain, cachexia, and cognitive dysfunction, is highlighted, and their translational relevance is discussed in the context of emerging neurotherapeutic strategies. This review provides an integrated conceptual framework that connects neurobiology, oncology, and immunology, thereby informing the development of nerve-targeted therapeutic strategies with potential to improve clinical outcomes in cancer.

Keywords

brain–body / comorbidity / drug repurposing / neuro-microbic-oncology / perineural invasion / tumor microenvironment

References

[1] Y.-F. Wang, Z.-K. Dong, and W.-L. Jin, “Hijacking Homeostasis: The Brain-body Neural Circuitry in Tumor Pathogenesis and Emerging Therapeutic Frontiers,” Molecular Cancer 24, no. 1 (2025): 206.

[2] M. Monje, J. C. Borniger, and N. J. D'Silva, “Roadmap for the Emerging Field of Cancer Neuroscience,” Cell 181, no. 2 (2020): 219–222.

[3] D. Hanahan and M. Monje, “Cancer Hallmarks Intersect With Neuroscience in the Tumor Microenvironment,” Cancer Cell 41, no. 3 (2023): 573–580.

[4] C. Swanton, E. Bernard, C. Abbosh, et al., “Embracing Cancer Complexity: Hallmarks of Systemic Disease,” Cell 187, no. 7 (2024): 1589–1616.

[5] S. I. Hajdu, “Greco-Roman Thought About Cancer,” Cancer 100, no. 10 (2004): 2048–2051.

[6] J. C. Holland, “History of Psycho-oncology: Overcoming Attitudinal and Conceptual Barr Iers,” Psychosomatic Medicine 64, no. 2 (2002): 206–221.

[7] S. Paget, “The Distribution of Secondary Growths in Cancer of the Breast. 1889,” Cancer and Metastasis Reviews 8, no. 2 (1989): 98–101.

[8] J. Folkman, “Tumor Angiogenesis: Therapeutic Implications,” New England Journal of Medicine 285, no. 21 (1971): 1182–1186.

[9] M. Z. Jin and W. L. Jin, “The Updated Landscape of Tumor Microenvironment and Drug Repurposing,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 166.

[10] D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer,” Cell 100, no. 1 (2000): 57–70.

[11] C. Magnon, S. J. Hall, J. Lin, et al., “Autonomic Nerve Development Contributes to Prostate Cancer Progression,” Science (New York, NY) 341, no. 6142 (2013): 1236361.

[12] C. M. Zhao, Y. Hayakawa, Y. Kodama, et al., “Denervation Suppresses Gastric Tumorigenesis,” Science Translational Medicine 6, no. 250 (2014): 250ra115.

[13] R. E. Stopczynski, D. P. Normolle, D. J. Hartman, et al., “Neuroplastic Changes Occur Early in the Development of Pancreatic Ductal Adenocarcinoma,” Cancer Research 74, no. 6 (2014): 1718–1727.

[14] S. C. Peterson, M. Eberl, A. N. Vagnozzi, et al., “Basal Cell Carcinoma Preferentially Arises From Stem Cells Within Hair Follicle and Mechanosensory Niches,” Cell Stem Cell 16, no. 4 (2015): 400–412.

[15] J. Pundavela, S. Roselli, S. Faulkner, et al., “Nerve Fibers Infiltrate the Tumor Microenvironment and Are Associated With Nerve Growth Factor Production and Lymph Node Invasion in Breast Cancer,” Molecular Oncology 9, no. 8 (2015): 1626–1635.

[16] B. W. Renz, T. Tanaka, M. Sunagawa, et al., “Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness,” Cancer Discovery 8, no. 11 (2018): 1458–1473.

[17] S. Faulkner, P. Jobling, B. March, C. C. Jiang, and H. Hondermarck, “Tumor Neurobiology and the War of Nerves in Cancer,” Cancer Discovery 9, no. 6 (2019): 702–710.

[18] S. M. Gysler and R. Drapkin, “Tumor Innervation: Peripheral Nerves Take Control of the Tumor Microenvironment,” Journal of Clinical Investigation 131, no. 11 (2021): e147276.

[19] S. S. Senga and R. P. Grose, “Hallmarks of Cancer-the New Testament,” Open Biology 11, no. 1 (2021): 200358.

[20] C. Magnon and H. Hondermarck, “The Neural Addiction of Cancer,” Nature Reviews Cancer 23, no. 5 (2023): 317–334.

[21] R. Mancusi and M. Monje, “The Neuroscience of Cancer,” Nature 618, no. 7965 (2023): 467–479.

[22] F. Winkler, H. S. Venkatesh, M. Amit, et al., “Cancer Neuroscience: State of the Field, Emerging Directions,” Cell 186, no. 8 (2023): 1689–1707.

[23] H. D. Reavis, H. I. Chen, and R. Drapkin, “Tumor Innervation: Cancer Has some Nerve,” Trends in Cancer 6, no. 12 (2020): 1059–1067.

[24] S. M. Knox, I. M. Lombaert, X. Reed, L. Vitale-Cross, J. S. Gutkind, and M. P. Hoffman, “Parasympathetic Innervation Maintains Epithelial Progenitor Cells During Salivary Organogenesis,” Science 329, no. 5999 (2010): 1645–1647.

[25] J. Kersigo and B. Fritzsch, “Inner Ear Hair Cells Deteriorate in Mice Engineered to Have no or Diminished Innervation,” Frontiers in Aging Neuroscience 7 (2015): 33.

[26] D. V. Bower, H.-K. Lee, R. Lansford, et al., “Airway Branching Has Conserved Needs for Local Parasympathetic Innerva Tion but Not Neurotransmission,” BMC Biology 12 (2014): 92.

[27] M. Puzan, S. Hosic, C. Ghio, and A. Koppes, “Enteric Nervous System Regulation of Intestinal Stem Cell Differentiation and Epithelial Monolayer Function,” Scientific Reports 8, no. 1 (2018): 6313.

[28] Y. Katayama, M. Battista, W. M. Kao, et al., “Signals From the Sympathetic Nervous System Regulate Hematopoietic Stem Cell Egress From Bone Marrow,” Cell 124, no. 2 (2006): 407–421.

[29] P. Carmeliet, “Blood Vessels and Nerves: Common Signals, Pathways and Diseases,” Nature Reviews Genetics 4, no. 9 (2003): 710–720.

[30] J. Geraudie and M. Singer, “Relation Between Nerve fiber Number and Pectoral Fin Regeneration in the Teleost,” Journal of Experimental Zoology 199, no. 1 (1977): 1–8.

[31] T. Endo, S. V. Bryant, and D. M. Gardiner, “A Stepwise Model System for Limb Regeneration,” Developmental Biology 270, no. 1 (2004): 135–145.

[32] R. Dantzer, “Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa,” Physiological Reviews 98, no. 1 (2018): 477–504.

[33] D. L. Felten, S. Y. Felten, S. L. Carlson, J. A. Olschowka, and S. Livnat, “Noradrenergic and Peptidergic Innervation of Lymphoid Tissue,” Journal of Immunology 135, no. 2 Suppl (1985): 755s–765s.

[34] K. J. Tracey, “The Inflammatory Reflex,” Nature 420, no. 6917 (2002): 853–859.

[35] M. Rosas-Ballina, P. S. Olofsson, M. Ochani, et al., “Acetylcholine-synthesizing T Cells Relay Neural Signals in a Vagus Nerve Circuit,” Science 334, no. 6052 (2011): 98–101.

[36] T. A. Ignatowski, S. Gallant, and R. N. Spengler, “Temporal Regulation by Adrenergic Receptor Stimulation of Macrophage (M phi)-derived Tumor Necrosis Factor (TNF) Production Post-LPS challen ge,” Journal of Neuroimmunology 65, no. 2 (1996): 107–117.

[37] C. A. Izeboud, J. A. Mocking, M. Monshouwer, A. S. van Miert, and R. F. Witkamp, “Participation of Beta-adrenergic Receptors on Macrophages in Modulatio n of LPS-induced Cytokine Release,” Journal of Receptor and Signal Transduction Research 19, no. 1-4 (1999): 191–202.

[38] C. J. Padro and V. M. Sanders, “Neuroendocrine Regulation of Inflammation,” Seminars in Immunology 26, no. 5 (2014): 357–368.

[39] R. N. Spengler, R. M. Allen, D. G. Remick, R. M. Strieter, and S. L. Kunkel, “Stimulation of Alpha-adrenergic Receptor Augments the Production of Ma Crophage-derived Tumor Necrosis Factor,” Journal of Immunology 145, no. 5 (1990): 1430–1434.

[40] K. Kawashima, T. Fujii, Y. Moriwaki, H. Misawa, and K. Horiguchi, “Reconciling Neuronally and Nonneuronally Derived Acetylcholine in the Regulation of Immune Function,” Annals of the New York Academy of Sciences 1261 (2012): 7–17.

[41] F. Marino and M. Cosentino, “Adrenergic Modulation of Immune Cells: An Update,” Amino Acids 45, no. 1 (2013): 55–71.

[42] Y.-H. Qiu, Y.-P. Peng, J.-M. Jiang, and J.-J. Wang, “Expression of Tyrosine Hydroxylase in Lymphocytes and Effect of Endoge Nous Catecholamines on Lymphocyte Function,” Neuroimmunomodulation 11, no. 2 (2004): 75–83.

[43] G. Talabér, M. Jondal, and S. Okret, “Extra-adrenal Glucocorticoid Synthesis: Immune Regulation and Aspects on Local Organ Homeostasis,” Molecular and Cellular Endocrinology 380, no. 1-2 (2013): 89–98.

[44] B. Boilly, S. Faulkner, P. Jobling, and H. Hondermarck, “Nerve Dependence: From Regeneration to Cancer,” Cancer Cell 31, no. 3 (2017): 342–354.

[45] M. Amit, H. Takahashi, M. P. Dragomir, et al., “Loss of p53 Drives Neuron Reprogramming in Head and Neck Cancer,” Nature 578, no. 7795 (2020): 449–454.

[46] A. C. Restaino, A. Walz, S. J. Vermeer, et al., “Functional Neuronal Circuits Promote Disease Progression in Cancer,” Science Advances 9, no. 19 (2023): eade4443.

[47] P. Mauffrey, N. Tchitchek, V. Barroca, et al., “Progenitors From the central Nervous System Drive Neurogenesis in Cancer,” Nature 569, no. 7758 (2019): 672–678.

[48] Y. Soda, T. Marumoto, D. Friedmann-Morvinski, et al., “Transdifferentiation of Glioblastoma Cells Into Vascular Endothelial Cells,” Proceedings of the National Academy of Sciences of the United States of America 108, no. 11 (2011): 4274–4280.

[49] R. Wang, K. Chadalavada, J. Wilshire, et al., “Glioblastoma Stem-Like Cells Give Rise to Tumour Endothelium,” Nature 468, no. 7325 (2010): 829–833.

[50] L. Ricci-Vitiani, R. Pallini, M. Biffoni, et al., “Tumour Vascularization via Endothelial Differentiation of Glioblastoma Stem-Like Cells,” Nature 468, no. 7325 (2010): 824–828.

[51] R. Lu, C. Fan, W. Shangguan, et al., “Neurons Generated From Carcinoma Stem Cells Support Cancer Progression,” Signal Transduction and Targeted Therapy 2 (2017): 16036.

[52] D. J. Salas-Escabillas, M. T. Hoffman, S. M. Brender, et al., “Tuft Cells Transdifferentiate to Neural-Like Progenitor Cells in the Progression of Pancreatic Cancer,” Developmental Cell 60, no. 6 (2024): 837–852.

[53] C. C. Jiang, M. Marsland, Y. Wang, et al., “Tumor Innervation Is Triggered by Endoplasmic Reticulum Stress,” Oncogene 41, no. 4 (2022): 586–599.

[54] R. S. Banh, D. E. Biancur, K. Yamamoto, et al., “Neurons Release Serine to Support mRNA Translation in Pancreatic Cancer,” Cell 183, no. 5 (2020): 1202–1218 e25.

[55] S.-H. Jiang, S. Zhang, Z. Cai, et al., “Mechnical cues of extracellular matrix determine tumor innervation,” BioRxiv (2024): 2024-03.

[56] S. Keller, A. K. Konig, F. Marme, et al., “Systemic Presence and Tumor-growth Promoting Effect of Ovarian Carcinoma Released Exosomes,” Cancer Letters 278, no. 1 (2009): 73–81.

[57] C. Thery, M. Ostrowski, and E. Segura, “Membrane Vesicles as Conveyors of Immune Responses,” Nature Reviews Immunology 9, no. 8 (2009): 581–593.

[58] M. Madeo, P. L. Colbert, D. W. Vermeer, et al., “Cancer Exosomes Induce Tumor Innervation,” Nature Communications 9, no. 1 (2018): 4284.

[59] C. T. Lucido, E. Wynja, M. Madeo, et al., “Innervation of Cervical Carcinoma Is Mediated by Cancer-derived Exosomes,” Gynecologic Oncology 154, no. 1 (2019): 228–235.

[60] A. Kovacs, D. W. Vermeer, and M. Madeo, Tumor-infiltrating Nerves Create an Electro-physiologically Active Microenvironment and Contribute to Treatment Resistance (Cold Spring Harbor Laboratory, 2020).

[61] Y. Hayakawa, K. Sakitani, M. Konishi, et al., “Nerve Growth Factor Promotes Gastric Tumorigenesis Through Aberrant Cholinergic Signaling,” Cancer Cell 31, no. 1 (2017): 21–34.

[62] X. Wang, Y. Fan, Q. Wang, et al., “Tumor-infiltrating Nerves: Unraveling the Role of Cancer Neuroscience in Tumorigenesis, Disease Progression, and Emerging Therapies,” Discover Oncology 16, no. 1 (2025): 1209.

[63] H. Wang, R. Huo, K. He, et al., “Perineural Invasion in Colorectal Cancer: Mechanisms of Action and Clinical Relevance,” Cellular Oncology (Dordrecht) 47, no. 1 (2024): 1–17.

[64] Y.-T. Li, W.-Z. Yuan, and W.-L. Jin, “Vagus Innervation in the Gastrointestinal Tumor: Current Understanding and Challenges,” Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1878, no. 3 (2023): 188884.

[65] S. Weil, M. Osswald, G. Solecki, et al., “Tumor Microtubes Convey Resistance to Surgical Lesions and Chemotherapy in Gliomas,” Neuro-Oncology 19, no. 10 (2017): 1316–1326.

[66] V. Venkataramani, Y. Yang, M. C. Schubert, et al., “Glioblastoma Hijacks Neuronal Mechanisms for Brain Invasion,” Cell 185, no. 16 (2022): 2899–2917 e31.

[67] M. Osswald, E. Jung, F. Sahm, et al., “Brain Tumour Cells Interconnect to a Functional and Resistant Network,” Nature 528, no. 7580 (2015): 93–98.

[68] S. R. Ali, M. Jordan, P. Nagarajan, and M. Amit, “Nerve Density and Neuronal Biomarkers in Cancer,” Cancers (Basel) 14, no. 19 (2022): 4817.

[69] H. Hondermarck and C. C. Jiang, “Time to Introduce Nerve Density in Cancer Histopathologic Assessment,” Clinical Cancer Research 29, no. 13 (2023): 2342–2344.

[70] H. S. Venkatesh, W. Morishita, A. C. Geraghty, et al., “Electrical and Synaptic Integration of Glioma Into Neural Circuits,” Nature 573, no. 7775 (2019): 539–545.

[71] V. Venkataramani, D. I. Tanev, C. Strahle, et al., “Glutamatergic Synaptic Input to Glioma Cells Drives Brain Tumour Progression,” Nature 573, no. 7775 (2019): 532–538.

[72] K. R. Taylor, T. Barron, A. Hui, et al., “Glioma Synapses Recruit Mechanisms of Adaptive Plasticity,” Nature 623, no. 7986 (2023): 366–374.

[73] F. S. Varn, K. C. Johnson, J. Martinek, et al., “Glioma Progression Is Shaped by Genetic Evolution and Microenvironment Interactions,” Cell 185, no. 12 (2022): 2184–2199 e16.

[74] D. D. Shi, J. A. Guo, H. I. Hoffman, et al., “Therapeutic Avenues for Cancer Neuroscience: Translational Frontiers and Clinical Opportunities,” The Lancet Oncology 23, no. 2 (2022): e62–e74.

[75] Y. Pan, J. D. Hysinger, T. Barron, et al., “NF1 mutation Drives Neuronal Activity-dependent Initiation of Optic Glioma,” Nature 594, no. 7862 (2021): 277–282.

[76] H. S. Venkatesh, T. B. Johung, V. Caretti, et al., “Neuronal Activity Promotes Glioma Growth Through Neuroligin-3 Secretion,” Cell 161, no. 4 (2015): 803–816.

[77] R. Drexler, R. Khatri, T. Sauvigny, et al., “A Prognostic Neural Epigenetic Signature in High-grade Glioma,” Nature Medicine 30, no. 6 (2024): 1622–1635.

[78] H. K. Lee, C. Xiang, S. Cazacu, et al., “GRP78 is Overexpressed in Glioblastomas and Regulates Glioma Cell Growth and Apoptosis,” Neuro-Oncology 10, no. 3 (2008): 236–243.

[79] R. N. Pearse, S. L. Swendeman, Y. Li, D. Rafii, and B. L. Hempstead, “A Neurotrophin Axis in Myeloma: TrkB and BDNF Promote Tumor-cell Survi Val,” Blood 105, no. 11 (2005): 4429–4436.

[80] H. Kobayashi, T. Iida, Y. Ochiai, et al., “Neuro-Mesenchymal Interaction Mediated by a beta2-Adrenergic Nerve Growth Factor Feedforward Loop Promotes Colorectal Cancer Progression,” Cancer Discovery 15, no. 1 (2025): 202–226.

[81] G. Hoover, S. Gilbert, O. Curley, et al., “Nerve-to-cancer Transfer of Mitochondria During Cancer Metastasis,” Nature 644, no. 8075 (2025): 252–262.

[82] A. H. Zahalka, A. Arnal-Estapé, M. Maryanovich, et al., “Adrenergic Nerves Activate an Angio-metabolic Switch in Prostate Cancer,” Science (New York, NY) 358, no. 6361 (2017): 321–326.

[83] Z. K. Dong, Y. F. Wang, W. P. Li, and W. L. Jin, “Neurobiology of Cancer: Adrenergic Signaling and Drug Repurposing,” Pharmacology & Therapeutics 264 (2024): 108750.

[84] C. Magnon, S. J. Hall, J. Lin, et al., “Autonomic Nerve Development Contributes to Prostate Cancer Progression,” Science 341, no. 6142 (2013): 1236361, https://www.science.org/doi/abs/10.1126/science.1236361.

[85] C.-M. Zhao, Y. Hayakawa, Y. Kodama, et al., “Denervation Suppresses Gastric Tumorigenesis,” Science Translational Medicine 6, no. 250 (2014): 250ra115, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374618/.

[86] S. A. Lyons, W. J. Chung, A. K. Weaver, T. Ogunrinu, and H. Sontheimer, “Autocrine Glutamate Signaling Promotes Glioma Cell Invasion,” Cancer Research 67, no. 19 (2007): 9463–9471.

[87] Y. Yang, L. Ren, W. Li, et al., “GABAergic Signaling as a Potential Therapeutic Target in Cancers,” Biomedicine & Pharmacotherapy 161 (2023): 114410.

[88] J. Tian and D. L. Kaufman, “The GABA and GABA-Receptor System in Inflammation, Anti-Tumor Immune Responses, and COVID-19,” Biomedicines 11, no. 2 (2023): 254.

[89] S. Forsgren, F. Landström, U. Kjörell, R. Henriksson, and L. Franzén, “Analysis of VIP and CGRP Plasma Levels after Radiotherapy for Treatment of Metastasis From Prostatic Carcinoma,” Annals of the New York Academy of Sciences 921, no. 1 (2000): 279–283, https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1749-6632.2000.tb06977.x.

[90] L. Jiang, Y. Zhou, S. Tang, et al., “Nociceptive Adenosine A_2AReceptor on Trigeminal Nerves Orc Hestrates CGRP Release to Regulate the Progression of Oral Squamous ce Ll Carcinoma,” International Journal of Oral Science 16, no. 1 (2024): 46.

[91] H. S. Venkatesh, L. T. Tam, P. J. Woo, et al., “Targeting Neuronal Activity-regulated Neuroligin-3 Dependency in High-grade Glioma,” Nature 549, no. 7673 (2017): 533–537.

[92] A. Androulidaki, E. Dermitzaki, M. Venihaki, et al., “Corticotropin Releasing Factor Promotes Breast Cancer Cell Motility and Invasiveness,” Molecular Cancer 8 (2009): 30.

[93] J. Yang, X. Gan, B. Tan, J. Wang, and Y. Chen, “Corticotropin-releasing Factor Suppresses Glioma Progression by Upregu Lation of Long Non-coding RNA-p21,” Life Sciences 216 (2019): 92–100.

[94] M. M. S. Obradovic, B. Hamelin, N. Manevski, et al., “Glucocorticoids Promote Breast Cancer Metastasis,” Nature 567, no. 7749 (2019): 540–544.

[95] E. K. Sloan, S. J. Priceman, B. F. Cox, et al., “The Sympathetic Nervous System Induces a Metastatic Switch in Primary Breast Cancer,” Cancer Research 70, no. 18 (2010): 7042–7052.

[96] H. Yang, L. Xia, J. Chen, et al., “Stress-glucocorticoid-TSC22D3 Axis Compromises Therapy-induced Antitumor Immunity,” Nature Medicine 25, no. 9 (2019): 1428–1441.

[97] H. Mohammadpour, C. R. MacDonald, G. Qiao, et al., “beta2 adrenergic Receptor-mediated Signaling Regulates the Immunosuppressive Potential of Myeloid-derived Suppressor Cells,” Journal of Clinical Investigation 129, no. 12 (2019): 5537–5552.

[98] S. H. Jiang, L. L. Zhu, M. Zhang, et al., “GABRP Regulates Chemokine Signalling, Macrophage Recruitment and Tumour Progression in Pancreatic Cancer Through Tuning KCNN4-mediated Ca(2+) Signalling in a GABA-independent Manner,” Gut 68, no. 11 (2019): 1994–2006.

[99] M. Chen, G. Qiao, B. L. Hylander, et al., “Adrenergic Stress Constrains the Development of Anti-tumor Immunity and Abscopal Responses Following Local Radiation,” Nature Communications 11, no. 1 (2020): 1821.

[100] M. Toda, T. Suzuki, K. Hosono, et al., “Neuronal System-dependent Facilitation of Tumor Angiogenesis and Tumor Growth by Calcitonin Gene-related Peptide,” Proceedings of the National Academy of Sciences of the United States of America 105, no. 36 (2008): 13550–13555.

[101] K. Y. Fjæstad, A. M. A. Rømer, V. Goitea, et al., “Blockade of Beta-adrenergic Receptors Reduces Cancer Growth and Enhanc es the Response to Anti-CTLA4 Therapy by Modulating the Tumor Microenv Ironment,” Oncogene 41, no. 9 (2022): 1364–1375.

[102] D. Hausmann, D. C. Hoffmann, V. Venkataramani, et al., “Autonomous Rhythmic Activity in Glioma Networks Drives Brain Tumour Gr Owth,” Nature 613, no. 7942 (2023): 179–186.

[103] J. S. Wefel, A. E. Kayl, and C. A. Meyers, “Neuropsychological Dysfunction Associated With Cancer and Cancer Therapies: A Conceptual Review of an Emerging Target,” British Journal of Cancer 90, no. 9 (2004): 1691–1696.

[104] N. P. Staff, A. Grisold, W. Grisold, and A. J. Windebank, “Chemotherapy-induced Peripheral Neuropathy: A Current Review,” Annals of Neurology 81, no. 6 (2017): 772–781.

[105] M. L. Monje, S. Mizumatsu, J. R. Fike, and T. D. Palmer, “Irradiation Induces Neural Precursor-cell Dysfunction,” Nature Medicine 8, no. 9 (2002): 955–962.

[106] M. L. Monje, H. Toda, and T. D. Palmer, “Inflammatory Blockade Restores Adult Hippocampal Neurogenesis,” Science 302, no. 5651 (2003): 1760–1765.

[107] E. M. Gibson, S. Nagaraja, A. Ocampo, et al., “Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation That Underlies Chemotherapy-Related Cognitive Impairment,” Cell 176, no. 1-2 (2019): 43–55 e13.

[108] M. L. Monje, H. Vogel, M. Masek, K. L. Ligon, P. G. Fisher, and T. D. Palmer, “Impaired human Hippocampal Neurogenesis After Treatment for central Nervous System Malignancies,” Annals of Neurology 62, no. 5 (2007): 515–520.

[109] A. C. Geraghty, E. M. Gibson, R. A. Ghanem, et al., “Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment,” Neuron 103, no. 2 (2019): 250–265 e8.

[110] C. Liebig, G. Ayala, J. A. Wilks, D. H. Berger, and D. Albo, “Perineural Invasion in Cancer: A Review of the Literature,” Cancer 115, no. 15 (2009): 3379–3391.

[111] L. Zhang, W. Zhang, X. Zhang, et al., “High‑Glucose Microenvironment Promotes Perineural Invasion of Pancreatic Cancer via Activation of Hypoxia Inducible Factor 1alpha,” Oncology Reports 47, no. 4 (2022): 64.

[112] J. Li, J. Ma, L. Han, et al., “Hyperglycemic Tumor Microenvironment Induces Perineural Invasion in Pancreatic Cancer,” Cancer Biology & Therapy 16, no. 6 (2015): 912–921.

[113] J. Nigri, M. Gironella, C. Bressy, et al., “PAP/REG3A Favors Perineural Invasion in Pancreatic Adenocarcinoma and Serves as a Prognostic Marker,” Cellular and Molecular Life Sciences 74, no. 22 (2017): 4231–4243.

[114] M. Amit, S. Na'ara, and Z. Gil, “Mechanisms of Cancer Dissemination Along Nerves,” Nature Reviews Cancer 16, no. 6 (2016): 399–408.

[115] E. Salvo, W. M. Campana, N. N. Scheff, et al., “Peripheral Nerve Injury and Sensitization Underlie Pain Associated wit h Oral Cancer Perineural Invasion,” Pain 161, no. 11 (2020): 2592–2602.

[116] E. Spekker, T. Körtési, and L. Vécsei, “TRP Channels: Recent Development in Translational Research and Potenti al Therapeutic Targets in Migraine,” International Journal of Molecular Sciences 24, no. 1 (2022): 700.

[117] C. R. Martin, V. Osadchiy, A. Kalani, and E. A. Mayer, “The Brain-Gut-Microbiome Axis,” Cellular and Molecular Gastroenterology and Hepatology 6, no. 2 (2018): 133–148.

[118] E. A. Mayer, “Gut Feelings: The Emerging Biology of Gut-brain Communication,” Nature Reviews Neuroscience 12, no. 8 (2011): 453–466.

[119] S. V. Mart'yanov, E. A. Botchkova, V. K. Plakunov, and A. V. Gannesen, “The Impact of Norepinephrine on Mono-Species and Dual-Species Staphylococcal Biofilms,” Microorganisms 9, no. 4 (2021): 820.

[120] C. Long-Smith, K. J. O'Riordan, G. Clarke, C. Stanton, T. G. Dinan, and J. F. Cryan, “Microbiota-Gut-Brain Axis: New Therapeutic Opportunities,” Annual Review of Pharmacology and Toxicology 60 (2020): 477–502.

[121] L. Liu, J. R. Huh, and K. Shah, “Microbiota and the Gut-brain-axis: Implications for New Therapeutic Design in the CNS,” EBioMedicine 77 (2022): 103908.

[122] M. Clapp, N. Aurora, L. Herrera, M. Bhatia, E. Wilen, and S. Wakefield, “Gut Microbiota's Effect on Mental Health: The Gut-brain Axis,” Clinics and Practice 7, no. 4 (2017): 987.

[123] K. Hou, Z. X. Wu, X. Y. Chen, et al., “Microbiota in Health and Diseases,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 135.

[124] X. Fan, A. V. Alekseyenko, J. Wu, et al., “Human Oral Microbiome and Prospective Risk for Pancreatic Cancer: A Population-based Nested Case-control Study,” Gut 67, no. 1 (2018): 120–127.

[125] W. Cao, Y. Liu, R. Zhang, et al., “Homoharringtonine Induces Apoptosis and Inhibits STAT3 via IL-6/JAK1/STAT3 Signal Pathway in Gefitinib-resistant Lung Cancer Cells,” Scientific Reports 5 (2015): 8477.

[126] K. Atarashi, W. Suda, C. Luo, et al., “Ectopic Colonization of Oral Bacteria in the Intestine Drives T_H1 Cell Induction and Inflammation,” Science (New York, NY) 358, no. 6361 (2017): 359–365.

[127] A. Patrizz, A. Dono, S. Zorofchian, et al., “Glioma and Temozolomide Induced Alterations in Gut Microbiome,” Scientific Reports 10, no. 1 (2020): 21002.

[128] A. L. Hung, T. Garzon-Muvdi, and M. Lim, “Biomarkers and Immunotherapeutic Targets in Glioblastoma,” World Neurosurgery 102 (2017): 494–506.

[129] Q. Ma, C. Xing, W. Long, H. Y. Wang, Q. Liu, and R. F. Wang, “Impact of Microbiota on central Nervous System and Neurological Diseases: The Gut-brain Axis,” Journal of Neuroinflammation 16, no. 1 (2019): 53.

[130] J. King, H. Mir, and S. Singh, “Association of Cytokines and Chemokines in Pathogenesis of Breast Canc er,” Progress in Molecular Biology and Translational Science 151 (2017): 113–136.

[131] P. Apostolova and E. L. Pearce, “Lactic Acid and Lactate: Revisiting the Physiological Roles in the Tum or Microenvironment,” Trends in Immunology 43, no. 12 (2022): 969–977.

[132] M. Artac and K. Altundag, “Leptin and Breast Cancer: An Overview,” Medical Oncology 29, no. 3 (2012): 1510–1514.

[133] M. Makale, “Cellular Mechanobiology and Cancer Metastasis,” Birth Defects Research Part C, Embryo Today 81, no. 4 (2007): 329–343.

[134] H. O. Besedovsky, A. del Rey, M. Schardt, et al., “Changes in Plasma Hormone Profiles After Tumor Transplantation Into Sy Ngeneic and Allogeneic Rats,” International Journal of Cancer 36, no. 2 (1985): 209–216.

[135] A. Bhaduri, E. Di Lullo, D. Jung, et al., “Outer Radial Glia-Like Cancer Stem Cells Contribute to Heterogeneity of Glioblastoma,” Cell Stem Cell 26, no. 1 (2020): 48–63 e6.

[136] Q. Zeng, I. P. Michael, P. Zhang, et al., “Synaptic Proximity Enables NMDAR Signalling to Promote Brain Metastasis,” Nature 573, no. 7775 (2019): 526–531.

[137] M. Prillaman, “How Cancer Hijacks the Nervous System to Grow and Spread,” Nature 626, no. 7997 (2024): 22–24.

[138] S. K. Tetzlaff, E. Reyhan, N. Layer, et al., “Characterizing and Targeting Glioblastoma Neuron-tumor Networks With R Etrograde Tracing,” Cell 188, no. 2 (2025): 390–411.e36.

[139] E. Huang-Hobbs, Y. T. Cheng, Y. Ko, et al., “Remote Neuronal Activity Drives Glioma Progression Through SEMA4F,” Nature 619, no. 7971 (2023): 844–850.

[140] P. Chen, W. Wang, R. Liu, et al., “Olfactory Sensory Experience Regulates Gliomagenesis via Neuronal IGF1,” Nature 606, no. 7914 (2022): 550–556.

[141] M. Weller, W. Wick, K. Aldape, et al., “Glioma,” Nature Reviews Disease Primers 1 (2015): 15017.

[142] V. Venkataramani, D. I. Tanev, T. Kuner, W. Wick, and F. Winkler, “Synaptic Input to Brain Tumors: Clinical Implications,” Neuro-Oncology 23, no. 1 (2021): 23–33.

[143] S. C. Buckingham, S. L. Campbell, B. R. Haas, et al., “Glutamate Release by Primary Brain Tumors Induces Epileptic Activity,” Nature Medicine 17, no. 10 (2011): 1269–1274.

[144] W. J. Chung, S. A. Lyons, G. M. Nelson, et al., “Inhibition of Cystine Uptake Disrupts the Growth of Primary Brain Tumors,” Journal of Neuroscience 25, no. 31 (2005): 7101–7110.

[145] M. Schneider, L. Vollmer, A. L. Potthoff, et al., “Meclofenamate Causes Loss of Cellular Tethering and Decoupling of Functional Networks in Glioblastoma,” Neuro-Oncology 23, no. 11 (2021): 1885–1897.

[146] M. Schneider, A. L. Potthoff, B. O. Evert, et al., “Inhibition of Intercellular Cytosolic Traffic via Gap Junctions Reinforces Lomustine-Induced Toxicity in Glioblastoma Independent of MGMT Promoter Methylation Status,” Pharmaceuticals (Basel) 14, no. 3 (2021): 195.

[147] Y. Zheng, L. Li, Z. Shen, et al., “Mechanisms of Neural Infiltration-mediated Tumor Metabolic Reprogramming Impacting Immunotherapy Efficacy in Non-small Cell Lung Cancer,” Journal of Experimental & Clinical Cancer Research 43, no. 1 (2024): 284.

[148] J. F. Wang, M. C. Wang, L. L. Jiang, and N. M. Lin, “The Neuroscience in Breast Cancer: Current Insights and Clinical Opportunities,” Heliyon 11, no. 3 (2025): e42293.

[149] J. W. L. Eng, K. M. Kokolus, C. B. Reed, B. L. Hylander, W. W. Ma, and E. A. Repasky, “A Nervous Tumor Microenvironment: The Impact of Adrenergic Stress on Cancer Cells, Immunosuppression, and Immunotherapeutic Response,” Cancer Immunology, Immunotherapy 63, no. 11 (2014): 1115–1128.

[150] T. Shan, Q. Ma, D. Zhang, et al., “beta2-adrenoceptor Blocker Synergizes With Gemcitabine to Inhibit the Proliferation of Pancreatic Cancer Cells via Apoptosis Induction,” European Journal of Pharmacology 665, no. 1-3 (2011): 1–7.

[151] D. Zhang, Q. Ma, Z. Wang, et al., “β2-adrenoceptor Blockage Induces G1/S Phase Arrest and Apoptosis in pa Ncreatic Cancer Cells via Ras/Akt/NFκB Pathway,” Molecular Cancer 10 (2011): 146.

[152] D. Zhang, Q. Y. Ma, H. T. Hu, and M. Zhang, “beta2-adrenergic Antagonists Suppress Pancreatic Cancer Cell Invasion by Inhibiting CREB, NFkappaB and AP-1,” Cancer Biology & Therapy 10, no. 1 (2010): 19–29.

[153] K. S. Sastry, Y. Karpova, S. Prokopovich, et al., “Epinephrine Protects Cancer Cells From Apoptosis via Activation of cAMP-dependent Protein Kinase and BAD Phosphorylation,” Journal of Biological Chemistry 282, no. 19 (2007): 14094–14100.

[154] F. Alessandrini, I. Cristofaro, M. Di Bari, J. Zasso, L. Conti, and A. M. Tata, “The Activation of M2 Muscarinic Receptor Inhibits Cell Growth and Surv Ival in human Glioblastoma Cancer Stem Cells,” International Immunopharmacology 29, no. 1 (2015): 105–109.

[155] R. Xu, C. Shang, J. Zhao, et al., “Activation of M3 Muscarinic Receptor by Acetylcholine Promotes Non-sma Ll Cell Lung Cancer Cell Proliferation and Invasion via EGFR/PI3K/AKT Pathway,” Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 36, no. 6 (2015): 4091–4100.

[156] M. Kodaira, M. Kajimura, K. Takeuchi, S. Lin, H. Hanai, and E. Kaneko, “Functional Muscarinic m3 Receptor Expressed in Gastric Cancer Cells st Imulates Tyrosine Phosphorylation and MAP Kinase,” Journal of Gastroenterology 34, no. 2 (1999): 163–171.

[157] K. Yagle, H. Lu, M. Guizzetti, T. Möller, and L. G. Costa, “Activation of Mitogen-activated Protein Kinase by Muscarinic Receptors in Astroglial Cells: Role in DNA Synthesis and Effect of Ethanol,” Glia 35, no. 2 (2001): 111–120.

[158] W. Song, M. Yuan, and S. Zhao, “Variation of M3 Muscarinic Receptor Expression in Different Prostate T Issues and Its Significance,” Saudi Medical Journal 30, no. 8 (2009): 1010–1016.

[159] S. Z. Young and A. Bordey, “GABA's Control of Stem and Cancer Cell Proliferation in Adult Neural and Peripheral Niches,” Physiology (Bethesda, Md) 24 (2009): 171–185.

[160] L. A. McIlvried, M. A. Atherton, N. L. Horan, T. N. Goch, and N. N. Scheff, “Sensory Neurotransmitter Calcitonin Gene-Related Peptide Modulates Tumor Growth and Lymphocyte Infiltration in Oral Squamous Cell Carcinoma,” Advanced Biology (Weinh) 6, no. 9 (2022): e2200019.

[161] S. Gutierrez and M. D. Boada, “Neuropeptide-induced Modulation of Carcinogenesis in a Metastatic Breast Cancer Cell Line (MDA-MB-231(LUC+)),” Cancer Cell International 18 (2018): 216.

[162] P. S. Olofsson, B. E. Steinberg, R. Sobbi, et al., “Blood Pressure Regulation by CD4(+) Lymphocytes Expressing Choline Acetyltransferase,” Nature Biotechnology 34, no. 10 (2016): 1066–1071.

[163] S. Huang, C. G. K. Ziegler, J. Austin, et al., “Lymph Nodes Are Innervated by a Unique Population of Sensory Neurons With Immunomodulatory Potential,” Cell 184, no. 2 (2021): 441–459 e25.

[164] M. Balood, M. Ahmadi, T. Eichwald, et al., “Nociceptor Neurons Affect Cancer Immunosurveillance,” Nature 611, no. 7935 (2022): 405–412.

[165] A. Y. Naser, A. N. Hameed, N. Mustafa, et al., “Depression and Anxiety in Patients with Cancer: A Cross-Sectional Study,” Frontiers in Psychology 12 (2021): 585534.

[166] A. Pitman, S. Suleman, N. Hyde, and A. Hodgkiss, “Depression and Anxiety in Patients With Cancer,” Bmj 361 (2018): k1415.

[167] J. J. Hue, H. J. Graor, M. Zarei, et al., “IDO1 Is a Therapeutic Target for Pancreatic Cancer-Associated Depression,” Molecular Cancer Therapeutics 21, no. 12 (2022): 1810–1822.

[168] G. Mantovani, A. Macciò, C. Madeddu, and E. Massa, “Cancer-related Cachexia and Oxidative Stress: Beyond Current Therapeut Ic Options,” Expert Review of Anticancer Therapy 3, no. 3 (2003): 381–392.

[169] C. N. Hunter, H. H. Abdel-Aal, W. A. Elsherief, D. E. Farag, N. M. Riad, and S. A. Alsirafy, “Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial,” Journal of Pain and Symptom Management 62, no. 6 (2021): 1207–1215.

[170] W. D. Dewys, C. Begg, P. T. Lavin, et al., “Prognostic Effect of Weight Loss Prior to Chemotherapy in Cancer Patie Nts. Eastern Cooperative Oncology Group,” American Journal of Medicine 69, no. 4 (1980): 491–497.

[171] S. C. Teunissen, W. Wesker, C. Kruitwagen, H. C. de Haes, E. E. Voest, and A. de Graeff, “Symptom Prevalence in Patients With Incurable Cancer: A Systematic Review,” Journal of Pain and Symptom Management 34, no. 1 (2007): 94–104.

[172] A. Inui, “Cancer Anorexia-cachexia Syndrome: Current Issues in Research and Management,” CA: A Cancer Journal for Clinicians 52, no. 2 (2002): 72–91.

[173] A. Molfino, A. Iannace, M. C. Colaiacomo, et al., “Cancer Anorexia: Hypothalamic Activity and Its Association With Inflammation and Appetite-regulating Peptides in Lung Cancer,” Journal of Cachexia, Sarcopenia and Muscle 8, no. 1 (2017): 40–47.

[174] C. C. Ezeoke and J. E. Morley, “Pathophysiology of Anorexia in the Cancer Cachexia Syndrome,” Journal of Cachexia, Sarcopenia and Muscle 6, no. 4 (2015): 287–302.

[175] A. Inui, “Neuropeptide Y: A Key Molecule in Anorexia and Cachexia in Wasting Dis Orders?,” Molecular Medicine Today 5, no. 2 (1999): 79–85.

[176] D. Gayle, S. E. Ilyin, and C. R. Plata-Salamán, “Central Nervous System IL-1 Beta System and Neuropeptide Y mRNAs During IL-1 Beta-induced Anorexia in Rats,” Brain Research Bulletin 44, no. 3 (1997): 311–317.

[177] A. Laviano, M. M. Meguid, Z. J. Yang, J. R. Gleason, C. Cangiano, and F. Rossi Fanelli, “Cracking the Riddle of Cancer Anorexia,” Nutrition (Burbank, Los Angeles County, Calif) 12, no. 10 (1996): 706–710.

[178] Z. J. Yang, V. Blaha, M. M. Meguid, A. Laviano, A. Oler, and Z. Zadak, “Interleukin-1alpha Injection Into Ventromedial Hypothalamic Nucleus of Normal Rats Depresses Food Intake and Increases Release of Dopamine a nd Serotonin,” Pharmacology Biochemistry and Behavior 62, no. 1 (1999): 61–65.

[179] W. A. Banks, S. A. Farr, and J. E. Morley, “Entry of Blood-borne Cytokines Into the central Nervous System: Effect s on Cognitive Processes,” Neuroimmunomodulation 10, no. 6 (2002): 319–327.

[180] A. Uehara, C. Sekiya, Y. Takasugi, M. Namiki, and A. Arimura, “Anorexia Induced by Interleukin 1: Involvement of Corticotropin-releas Ing Factor,” American Journal of Physiology 257, no. 3 Pt 2 (1989): R613–R617.

[181] G. F. Torelli, M. M. Meguid, L. L. Moldawer, et al., “Use of Recombinant human Soluble TNF Receptor in Anorectic Tumor-beari Ng Rats,” American Journal of Physiology 277, no. 3 (1999): R850–R855.

[182] E. G. Gutierrez, W. A. Banks, and A. J. Kastin, “Murine Tumor Necrosis Factor Alpha Is Transported From Blood to Brain in the Mouse,” Journal of Neuroimmunology 47, no. 2 (1993): 169–176.

[183] L. E. Goehler, C. R. Busch, N. Tartaglia, et al., “Blockade of Cytokine Induced Conditioned Taste Aversion by Subdiaphrag Matic Vagotomy: Further Evidence for Vagal Mediation of Immune-brain c Ommunication,” Neuroscience Letters 185, no. 3 (1995): 163–166.

[184] M. A. Borg, W. V. Tamborlane, G. I. Shulman, and R. S. Sherwin, “Local Lactate Perfusion of the Ventromedial Hypothalamus Suppresses Hy Poglycemic Counterregulation,” Diabetes 52, no. 3 (2003): 663–666.

[185] A. Kokorovic, G. W. C. Cheung, L. Rossetti, and T. K. T. Lam, “Hypothalamic Sensing of Circulating Lactate Regulates Glucose Producti on,” Journal of Cellular and Molecular Medicine 13, no. 11-12 (2009): 4403–4408.

[186] C. K. Lam, M. Chari, and T. K. Lam, “CNS Regulation of Glucose Homeostasis,” Physiology (Bethesda, Md) 24 (2009): 159–170.

[187] C. K. L. Lam, M. Chari, P. Y. T. Wang, and T. K. T. Lam, “Central Lactate Metabolism Regulates Food Intake,” American Journal of Physiology. Endocrinology and Metabolism 295, no. 2 (2008): E491–E496.

[188] P. M. Myrianthefs and C. Batistaki, “Cancer Cachexia and Immunomodulation,” Journal of BUON 10, no. 2 (2005): 181–188.

[189] O. C. Lindner, B. Phillips, M. G. McCabe, et al., “A Meta-analysis of Cognitive Impairment Following Adult Cancer Chemotherapy,” Neuropsychology 28, no. 5 (2014): 726–740.

[190] F. Joly, B. Giffard, O. Rigal, et al., “Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research from the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012,” Journal of Pain and Symptom Management 50, no. 6 (2015): 830–841.

[191] A. L. Whittaker, R. P. George, and L. O'Malley, “Prevalence of Cognitive Impairment Following Chemotherapy Treatment for Breast Cancer: A Systematic Review and Meta-analysis,” Scientific Reports 12, no. 1 (2022): 2135.

[192] A. B. C. Dijkshoorn, H. E. van Stralen, M. Sloots, S. B. Schagen, J. M. A. Visser-Meily, and V. P. M. Schepers, “Prevalence of Cognitive Impairment and Change in Patients With Breast Cancer: A Systematic Review of Longitudinal Studies,” Psycho-Oncology 30, no. 5 (2021): 635–648.

[193] M. Songbo, H. Lang, C. Xinyong, X. Bin, Z. Ping, and S. Liang, “Oxidative Stress Injury in Doxorubicin-induced Cardiotoxicity,” Toxicology Letters 307 (2019): 41–48.

[194] Y. Chen, P. Jungsuwadee, M. Vore, D. A. Butterfield, and D. K. St Clair, “Collateral Damage in Cancer Chemotherapy: Oxidative Stress in Nontarge Ted Tissues,” Molecular Interventions 7, no. 3 (2007): 147–156.

[195] H. E. Poulsen, E. Specht, K. Broedbaek, et al., “RNA Modifications by Oxidation: A Novel Disease Mechanism?,” Free Radical Biology and Medicine 52, no. 8 (2012): 1353–1361.

[196] A. M. Williams, R. Shah, M. Shayne, et al., “Associations Between Inflammatory Markers and Cognitive Function in Breast Cancer Patients Receiving Chemotherapy,” Journal of Neuroimmunology 314 (2018): 17–23.

[197] A. L. Andres, X. Gong, K. Di, and D. A. Bota, “Low-doses of Cisplatin Injure Hippocampal Synapses: A Mechanism for ‘Chemo’ brain?,” Experimental Neurology 255 (2014): 137–144.

[198] N. Tay, E. L. Laakso, D. Schweitzer, R. Endersby, I. Vetter, and H. Starobova, “Chemotherapy-induced Peripheral Neuropathy in Children and Adolescent Cancer Patients,” Frontiers in Molecular Biosciences 9 (2022): 1015746.

[199] M. R. Trendowski, C. M. Lusk, J. J. Ruterbusch, et al., “Chemotherapy-induced Peripheral Neuropathy in African American Cancer Survivors: Risk Factors and Quality of Life Outcomes,” Cancer Medicine 10, no. 22 (2021): 8151–8161.

[200] M. Omran, E. K. Belcher, N. A. Mohile, et al., “Review of the Role of the Brain in Chemotherapy-Induced Peripheral Neuropathy,” Frontiers in Molecular Biosciences 8 (2021): 693133.

[201] P. Verma, M. Eaton, A. Kienle, D. Flockerzi, Y. Yang, and D. Ramkrishna, “Examining Sodium and Potassium Channel Conductances Involved in Hyperexcitability of Chemotherapy-Induced Peripheral Neuropathy: A Mathematical and Cell Culture-Based Study,” Frontiers in Computational Neuroscience 14 (2020): 564980.

[202] L. Brandolini, M. d'Angelo, A. Antonosante, M. Allegretti, and A. Cimini, “Chemokine Signaling in Chemotherapy-Induced Neuropathic Pain,” International Journal of Molecular Sciences 20, no. 12 (2019): 2904.

[203] L. M. Bolin, A. N. Verity, J. E. Silver, E. M. Shooter, and J. S. Abrams, “Interleukin-6 Production by Schwann Cells and Induction in Sciatic Ner Ve Injury,” Journal of Neurochemistry 64, no. 2 (1995): 850–858.

[204] Y. H. Shin, S. J. Lee, and J. Jung, “Secretion of ATP From Schwann Cells Through Lysosomal Exocytosis durin G Wallerian Degeneration,” Biochemical and Biophysical Research Communications 429, no. 3-4 (2012): 163–167.

[205] G. K. Tofaris, P. H. Patterson, K. R. Jessen, and R. Mirsky, “Denervated Schwann Cells Attract Macrophages by Secretion of Leukemia Inhibitory Factor (LIF) and Monocyte Chemoattractant Protein-1 in a pr Ocess Regulated by Interleukin-6 and LIF,” The Journal of neuroscience: the official journal of the Society for Neuroscience 22, no. 15 (2002): 6696–6703.

[206] A. Canta, E. Pozzi, and V. A. Carozzi, “Mitochondrial Dysfunction in Chemotherapy-Induced Peripheral Neuropathy (CIPN),” Toxics 3, no. 2 (2015): 198–223.

[207] P. Silva Santos Ribeiro, H. Willemen, and N. Eijkelkamp, “Mitochondria and Sensory Processing in Inflammatory and Neuropathic Pain,” Frontiers in Pain Research (Lausanne) 3 (2022): 1013577.

[208] M. Cuozzo, V. Castelli, C. Avagliano, et al., “Effects of Chronic Oral Probiotic Treatment in Paclitaxel-Induced Neuropathic Pain,” Biomedicines 9, no. 4 (2021): 346.

[209] H. Breivik, N. Cherny, B. Collett, et al., “Cancer-related Pain: A pan-European Survey of Prevalence, Treatment, and Patient Attitudes,” Annals of Oncology 20, no. 8 (2009): 1420–1433.

[210] E. Osmialowska, W. Misiag, M. Chabowski, and B. Jankowska-Polanska, “Coping Strategies, Pain, and Quality of Life in Patients With Breast Cancer,” Journal of Clinical Medicine 10, no. 19 (2021): 4469.

[211] M. Evenepoel, V. Haenen, T. De Baerdemaecker, et al., “Pain Prevalence during Cancer Treatment: A Systematic Review and Meta- Analysis,” Journal of Pain and Symptom Management 63, no. 3 (2022): e317–e335.

[212] R. E. Coleman, “Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity,” Clinical Cancer Research 12, no. 20 Pt 2 (2006): 6243s–6249s.

[213] S. Mercadante, “Malignant Bone Pain: Pathophysiology and Treatment,” Pain 69, no. 1-2 (1997): 1–18.

[214] A. Bellahcene, R. Bachelier, C. Detry, R. Lidereau, P. Clezardin, and V. Castronovo, “Transcriptome Analysis Reveals an Osteoblast-Like Phenotype for human Osteotropic Breast Cancer Cells,” Breast Cancer Research and Treatment 101, no. 2 (2007): 135–148.

[215] J. Akech, J. J. Wixted, K. Bedard, et al., “Runx2 association With Progression of Prostate Cancer in Patients: Mechanisms Mediating Bone Osteolysis and Osteoblastic Metastatic Lesions,” Oncogene 29, no. 6 (2010): 811–821.

[216] T. L. Andersen, P. Boissy, T. E. Sondergaard, et al., “Osteoclast Nuclei of myeloma Patients Show Chromosome Translocations s Pecific for the myeloma Cell Clone: A New Type of Cancer-host Partners hip?,” Journal of Pathology 211, no. 1 (2007): 10–17.

[217] M. Nagae, T. Hiraga, and T. Yoneda, “Acidic Microenvironment Created by Osteoclasts Causes Bone Pain Associated With Tumor Colonization,” Journal of Bone and Mineral Metabolism 25, no. 2 (2007): 99–104.

[218] W. Chen, H. Li, X. Hao, and C. Liu, “TRPV1 in Dorsal Root Ganglion Contributed to Bone Cancer Pain,” Frontiers in Pain Research (Lausanne) 3 (2022): 1022022.

[219] F. Aielli, M. Ponzetti, and N. Rucci, “Bone Metastasis Pain, From the Bench to the Bedside,” International Journal of Molecular Sciences 20, no. 2 (2019): 280.

[220] M. A. C. Sabino, J. R. Ghilardi, J. L. M. Jongen, et al., “Simultaneous Reduction in Cancer Pain, Bone Destruction, and Tumor Gro Wth by Selective Inhibition of Cyclooxygenase-2,” Cancer Research 62, no. 24 (2002): 7343–7349.

[221] M. Sayilekshmy, R. B. Hansen, J. M. Delaisse, L. Rolighed, T. L. Andersen, and A. M. Heegaard, “Innervation Is Higher Above Bone Remodeling Surfaces and in Cortical Pores in Human Bone: Lessons From Patients With Primary Hyperparathyroidism,” Scientific Reports 9, no. 1 (2019): 5361.

[222] S. Nencini and J. Ivanusic, “Mechanically Sensitive Aδ Nociceptors That Innervate Bone Marrow Respo nd to Changes in Intra-osseous Pressure,” The Journal of Physiology 595, no. 13 (2017): 4399–4415.

[223] J. L. Sottnik, J. Dai, H. Zhang, B. Campbell, and E. T. Keller, “Tumor-induced Pressure in the Bone Microenvironment Causes Osteocytes to Promote the Growth of Prostate Cancer Bone Metastases,” Cancer Research 75, no. 11 (2015): 2151–2158.

[224] C. M. Peters, J. R. Ghilardi, C. P. Keyser, et al., “Tumor-induced Injury of Primary Afferent Sensory Nerve Fibers in Bone Cancer Pain,” Experimental Neurology 193, no. 1 (2005): 85–100.

[225] Z. Zhu, H. Friess, F. F. diMola, et al., “Nerve Growth Factor Expression Correlates with Perineural Invasion and Pain in Human Pancreatic Cancer,” Journal of Clinical Oncology 17, no. 8 (1999): 2419–2419.

[226] F. F. di Mola and P. di Sebastiano, “Pain and Pain Generation in Pancreatic Cancer,” Langenbecks Archives of Surgery 393, no. 6 (2008): 919–922.

[227] G. O. Ceyhan, C. W. Michalski, I. E. Demir, M. W. Muller, and H. Friess, “Pancreatic Pain,” Best Practice & Research Clinical Gastroenterology 22, no. 1 (2008): 31–44.

[228] D. K. Lam and B. L. Schmidt, “Serine Proteases and Protease-activated Receptor 2-dependent Allodynia: A Novel Cancer Pain Pathway,” Pain 149, no. 2 (2010): 263–272.

[229] A. Buttner-Teleaga, Y. T. Kim, T. Osel, and K. Richter, “Sleep Disorders in Cancer-A Systematic Review,” International Journal of Environmental Research and Public Health 18, no. 21 (2021): 11696.

[230] S. Sephton and D. Spiegel, “Circadian Disruption in Cancer: A Neuroendocrine-immune Pathway From s Tress to Disease?,” Brain, Behavior, and Immunity 17, no. 5 (2003): 321–328.

[231] A. Amidi and L. M. Wu, “Circadian Disruption and Cancer- and Treatment-related Symptoms,” Frontiers in Oncology 12 (2022): 1009064.

[232] S. A. Mitchell, “Cancer-related Fatigue: State of the Science,” PM & R 2, no. 5 (2010): 364–383.

[233] J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow, “Mechanisms of Cancer-related Fatigue,” The Oncologist 12, no. Suppl 1 (2007): 22–34.

[234] A. D. Crosswell, K. G. Lockwood, P. A. Ganz, and J. E. Bower, “Low Heart Rate Variability and Cancer-related Fatigue in Breast Cancer Survivors,” Psychoneuroendocrinology 45 (2014): 58–66.

[235] C. P. Fagundes, D. M. Murray, B. S. Hwang, et al., “Sympathetic and Parasympathetic Activity in Cancer-related Fatigue: More Evidence for a Physiological Substrate in Cancer Survivors,” Psychoneuroendocrinology 36, no. 8 (2011): 1137–1147.

[236] K. Esposito, P. Chiodini, A. Colao, A. Lenzi, and D. Giugliano, “Metabolic Syndrome and Risk of Cancer: A Systematic Review and Meta-analysis,” Diabetes Care 35, no. 11 (2012): 2402–2411.

[237] A. Schrepf, P. H. Thaker, M. J. Goodheart, et al., “Diurnal Cortisol and Survival in Epithelial Ovarian Cancer,” Psychoneuroendocrinology 53 (2015): 256–267.

[238] A. E. Vinas-Mendieta, A. Gallardo-Grajeda, and T. Lopez-Fernandez, “Cardio-oncology: Chances and Challenges,” Basic Research in Cardiology 120, no. 1 (2024): 3–9.

[239] A. F. Mavrogenis, P. J. Papagelopoulos, M. Romantini, A. Angelini, and P. Ruggieri, “Side Effects of Chemotherapy in Musculoskeletal Oncology,” Journal of Long-Term Effects of Medical Implants 20, no. 1 (2010): 1–12.

[240] R. A. de Boer, W. C. Meijers, P. van der Meer, and D. J. van Veldhuisen, “Cancer and Heart Disease: Associations and Relations,” European Journal of Heart Failure 21, no. 12 (2019): 1515–1525.

[241] B. P. Goodman and S. L. Schrader, “Radiation-induced Cranial Neuropathies Manifesting as Baroreflex Failu Re and Progressive Bulbar Impairment,” The Neurologist 15, no. 2 (2009): 102–104.

[242] L. Kong, J. J. Lu, A. L. Liss, et al., “Radiation-induced Cranial Nerve Palsy: A Cross-sectional Study of Naso Pharyngeal Cancer Patients After Definitive Radiotherapy,” International Journal of Radiation and Oncology in Biology and Physics 79, no. 5 (2011): 1421–1427.

[243] K. Ananthan and A. R. Lyon, “The Role of Biomarkers in Cardio-Oncology,” Journal of Cardiovascular Translational Research 13, no. 3 (2020): 431–450.

[244] A. R. Lyon, T. Lopez-Fernandez, L. S. Couch, et al., “2022 ESC Guidelines on Cardio-oncology Developed in Collaboration With the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS),” European Heart Journal 43, no. 41 (2022): 4229–4361.

[245] A. Yap, M. A. Lopez-Olivo, J. Dubowitz, et al., “Effect of Beta-blockers on Cancer Recurrence and Survival: A Meta-analysis of Epidemiological and Perioperative Studies,” British Journal of Anaesthesia 121, no. 1 (2018): 45–57.

[246] K. Shchors, A. Massaras, and D. Hanahan, “Dual Targeting of the Autophagic Regulatory Circuitry in Gliomas With Repurposed Drugs Elicits Cell-Lethal Autophagy and Therapeutic Benefit,” Cancer Cell 28, no. 4 (2015): 456–471.

[247] S. A. Grossman, X. Ye, M. Chamberlain, et al., “Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial,” Journal of Clinical Oncology 27, no. 25 (2009): 4155–4161.

[248] E. Aronica, E. Ciusani, A. Coppola, et al., “Epilepsy and Brain Tumors: Two Sides of the Same Coin,” Journal of the Neurological Sciences 446 (2023): 120584.

[249] R. Bhardwaj, J. L. Collins, J. Stringfellow, et al., “P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibi Tion by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rim Egepant in Healthy Subjects,” Clinical Pharmacology in Drug Development 11, no. 7 (2022): 889–897.

[250] E. Y. Tükel, O. Ateş, and Y. Kiraz, “In Silico Drug Repurposing against PSMB8 as a Potential Target for Acu te Myeloid Leukemia Treatment,” Molecular Biotechnology 67, no. 7 (2024): 2617–2627.

[251] X. Sun, M. Lin, Z. Tian, Y. Ma, and L. Lv, “GABA/baclofen Stabilizes PD-L1 and Enhances Immunotherapy of Breast Cancer,” Heliyon 10, no. 7 (2024): e28600.

[252] Q.-Q. Yin, L.-H. Xu, M. Zhang, and C. Xu, “Muscarinic Acetylcholine Receptor M1 Mediates Prostate Cancer Cell Mig Ration and Invasion Through Hedgehog Signaling,” Asian Journal of Andrology 20, no. 6 (2018): 608–614.

[253] F. Naznin, T. M. Z. Waise, and P. Fernyhough, “Antagonism of the Muscarinic Acetylcholine Type 1 Receptor Enhances Mi Tochondrial Membrane Potential and Expression of Respiratory Chain Com Ponents via AMPK in Human Neuroblastoma SH-SY5Y Cells and Primary Neur Ons,” Molecular Neurobiology 59, no. 11 (2022): 6754–6770.

[254] M. Srivastava, N. Brito-Dellan, M. P. Davis, M. Leach, and R. Lagman, “Olanzapine as an Antiemetic in Refractory Nausea and Vomiting in advan Ced Cancer,” Journal of Pain and Symptom Management 25, no. 6 (2003): 578–582.

[255] N. Kuol, M. Davidson, J. Karakkat, et al., “Blocking Muscarinic Receptor 3 Attenuates Tumor Growth and Decreases I Mmunosuppressive and Cholinergic Markers in an Orthotopic Mouse Model of Colorectal Cancer,” International Journal of Molecular Sciences 24, no. 1 (2022): 596.

[256] S. M. Larabee, K. Cheng, J.-P. Raufman, and S. Hu, “Muscarinic Receptor Activation in Colon Cancer Selectively Augments pr o-proliferative microRNA-21, microRNA-221 and microRNA-222 Expression,” PLoS ONE 17, no. 6 (2022): e0269618.

[257] E. A. Ahmed, M. A. Alkuwayti, and H.-I. M. Ibrahim, “Atropine Is a Suppressor of Epithelial-Mesenchymal Transition (EMT) Th at Reduces Stemness in Drug-Resistant Breast Cancer Cells,” International Journal of Molecular Sciences 23, no. 17 (2022): 9849.

[258] X. Zhang, Y. Zhang, Z. He, et al., “Chronic Stress Promotes Gastric Cancer Progression and Metastasis: An Essential Role for ADRB2,” Cell Death & Disease 10, no. 11 (2019): 788.

[259] G. Talarico, S. Orecchioni, K. Dallaglio, et al., “Aspirin and atenolol Enhance Metformin Activity Against Breast Cancer by Targeting both Neoplastic and Microenvironment Cells,” Scientific Reports 6 (2016): 18673.

[260] O. D. Işeri, F. I. Sahin, Y. K. Terzi, E. Yurtcu, S. R. Erdem, and F. Sarialioglu, “beta-Adrenoreceptor Antagonists Reduce Cancer Cell Proliferation, Inva Sion, and Migration,” Pharmaceutical Biology 52, no. 11 (2014): 1374–1381.

[261] A. Wihandono, Y. Azhar, M. Abdurahman, and S. Hidayat, “The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients,” Asian Pacific Journal of Cancer Prevention 22, no. 9 (2021): 2847–2853.

[262] L. Yuan, J. Springer, S. Palus, et al., “The atypical β-blocker S-oxprenolol Reduces Cachexia and Improves Surv Ival in a Rat Cancer Cachexia Model,” Journal of Cachexia, Sarcopenia and Muscle 14, no. 1 (2023): 653–660.

[263] M. Lee, W.-B. Chung, J.-E. Lee, et al., “Candesartan and carvedilol for Primary Prevention of Subclinical Cardi Otoxicity in Breast Cancer Patients Without a Cardiovascular Risk Trea Ted With doxorubicin,” Cancer Medicine 10, no. 12 (2021): 3964–3973.

[264] R. D. Gillis, E. Botteri, A. Chang, et al., “Carvedilol Blocks Neural Regulation of Breast Cancer Progression in vi vo and Is Associated With Reduced Breast Cancer Mortality in Patients,” European Journal of Cancer 147 (2021): 106–116.

[265] P. A. Henriksen, P. Hall, I. R. MacPherson, et al., “Multicenter, Prospective, Randomized Controlled Trial of High-Sensitiv Ity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockad E and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: Th E Cardiac CARE Trial,” Circulation 148, no. 21 (2023): 1680–1690.

[266] R. Ray, H. Al Khashali, and B. Haddad, “Regulation of Cisplatin Resistance in Lung Cancer Cells by Nicotine, B DNF, and a β-Adrenergic Receptor Blocker,” International Journal of Molecular Sciences 23, no. 21 (2022): 12829.

[267] Y. Lin, Y. Liu, Z. Gao, et al., “Beta-adrenergic Receptor Blocker Propranolol Triggers Anti-tumor Immun Ity and Enhances Irinotecan Therapy in Mice Colorectal Cancer,” European Journal of Pharmacology 949 (2023): 175718.

[268] M. Koh, T. Takahashi, Y. Kurokawa, et al., “Propranolol Suppresses Gastric Cancer Cell Growth by Regulating Prolif Eration and Apoptosis,” Gastric Cancer 24, no. 5 (2021): 1037–1049.

[269] B. Zheng, P. Du, Z. Zeng, P. Cao, X. Ma, and Y. Jiang, “Propranolol Inhibits EMT and Metastasis in Breast Cancer Through miR-4 99-5p-mediated Sox6,” Journal of Cancer Research and Clinical Oncology 150, no. 2 (2024): 59.

[270] T. P. Uccello, M. L. Lesch, N. A. Ullman, et al., “Radiation Therapy Exacerbates Tumor-Promoting Innervation and Nerve Si Gnaling in Rectal Cancer,” International Journal of Radiation and Oncology in Biology and Physics 115, no. 3 (2023): 733–745.

[271] X. Cao, Y. Yang, W. Zhou, et al., “Aprepitant Inhibits the Development and Metastasis of Gallbladder Canc er via ROS and MAPK Activation,” BMC Cancer 23, no. 1 (2023): 471.

[272] J. A. Smith, A. Harle, R. Dockry, et al., “Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled T Rial and Mechanistic Insights,” American Journal of Respiratory and Critical Care Medicine 203, no. 6 (2021): 737–745.

[273] A. AlAlikhan, A. Ghahremanloo, H. Javid, S. Ebrahimi, and S. I. Hashemy, “The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Infl Ammatory and Apoptosis Pathways in Human Ovarian Cancer Cells,” Cell Biochemistry and Biophysics 80, no. 4 (2022): 819–827.

[274] S. Ebrahimi, F. Mirzavi, S. I. Hashemy, M. Khaleghi Ghadiri, W. Stummer, and A. Gorji, “The in Vitro Anti-cancer Synergy of Neurokinin-1 Receptor Antagonist, Aprepitant, and 5-aminolevulinic Acid in Glioblastoma,” Biofactors 49, no. 4 (2023): 900–911.

[275] Y. Yang, X. Cao, Y. Wang, et al., “Neurokinin-1 Receptor Antagonist Aprepitant Regulates Autophagy and Ap Optosis via ROS/JNK in Intrahepatic Cholangiocarcinoma,” Liver International 44, no. 7 (2024): 1651–1667.

[276] E. Ribeiro, D. Araújo, M. Pereira, et al., “Repurposing Benztropine, Natamycin, and Nitazoxanide Using Drug Combin Ation and Characterization of Gastric Cancer Cell Lines,” Biomedicines 11, no. 3 (2023): 799.

[277] D. Duarte, A. Rêma, I. Amorim, and N. Vale, “Drug Combinations: A New Strategy to Extend Drug Repurposing and Epith Elial-Mesenchymal Transition in Breast and Colon Cancer Cells,” Biomolecules 12, no. 2 (2022): 190.

[278] O. Cerles, T. C. Gonçalves, S. Chouzenoux, et al., “Preventive Action of Benztropine on Platinum-induced Peripheral Neurop Athies and Tumor Growth,” Acta Neuropathologica Communications 7, no. 1 (2019): 9.

[279] D. Duarte, M. Nunes, S. Ricardo, and N. Vale, “Combination of Antimalarial and CNS Drugs With Antineoplastic Agents i n MCF-7 Breast and HT-29 Colon Cancer Cells: Biosafety Evaluation and Mechanism of Action,” Biomolecules 12, no. 10 (2022): 1490.

[280] C. Sogawa, T. Eguchi, M. T. Tran, et al., “Antiparkinson Drug Benztropine Suppresses Tumor Growth, Circulating Tu Mor Cells, and Metastasis by Acting on SLC6A3/DAT and Reducing STAT3,” Cancers 12, no. 2 (2020): 523.

[281] D. Duarte, A. Cardoso, and N. Vale, “Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer C Ells With Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs,” International Journal of Molecular Sciences 22, no. 14 (2021): 7408.

[282] G. Qian, L. Dai, and T. Yu, “Thioridazine Sensitizes Cisplatin against Chemoresistant Human Lung an D Ovary Cancer Cells,” DNA and Cell Biology 38, no. 7 (2019): 718–724.

[283] Z.-Y. Yang, Y.-W. Zhao, J.-R. Xue, et al., “Thioridazine Reverses Trastuzumab Resistance in Gastric Cancer by Inhi Biting S-phase Kinase Associated Protein 2-mediated Aerobic Glycolysis,” World Journal of Gastroenterology 29, no. 45 (2023): 5974–5987.

[284] S. Kang, S. M. Dong, B.-R. Kim, et al., “Thioridazine Induces Apoptosis by Targeting the PI3K/Akt/mTOR Pathway in Cervical and Endometrial Cancer Cells,” Apoptosis 17, no. 9 (2012): 989–997.

[285] S. U. Seo, H. K. Cho, K.-J. Min, et al., “Thioridazine Enhances Sensitivity to Carboplatin in human Head and Nec k Cancer Cells Through Downregulation of c-FLIP and Mcl-1 Expression,” Cell Death & Disease 8, no. 2 (2017): e2599.

[286] T.-H. Tran, M. Kao, H.-S. Liu, Y.-R. Hong, Y. Su, and C.-Y. F. Huang, “Repurposing Thioridazine for Inducing Immunogenic Cell Death in Colore Ctal Cancer via eIF2α/ATF4/CHOP and Secretory Autophagy Pathways,” Cell Communication and Signaling 21, no. 1 (2023): 184.

[287] X. Jin, B. Zou, L. Luo, et al., “Codelivery of Thioridazine and Doxorubicin Using Nanoparticles for Eff Ective Breast Cancer Therapy,” International Journal of Nanomedicine 11 (2016): 4545–4552.

[288] S. Venneti, A. R. Kawakibi, S. Ji, et al., “Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas I s Driven by Disruption of Integrated Metabolic and Epigenetic Pathways,” Cancer Discovery 13, no. 11 (2023): 2370–2393.

[289] V. Kumar, B. Sethi, D. W. Staller, P. Shrestha, and R. I. Mahato, “Gemcitabine elaidate and ONC201 Combination Therapy for Inhibiting Pan Creatic Cancer in a KRAS Mutated Syngeneic Mouse Model,” Cell Death Discovery 10, no. 1 (2024): 158.

[290] B. Lim, C. B. Peterson, A. Davis, et al., “ONC201 and an MEK Inhibitor Trametinib Synergistically Inhibit the Gro Wth of Triple-Negative Breast Cancer Cells,” Biomedicines 9, no. 10 (2021): 1410.

[291] A. Mishukov, I. Odinokova, E. Mndlyan, et al., “ONC201-Induced Mitochondrial Dysfunction, Senescence-Like Phenotype, a nd Sensitization of Cultured BT474 Human Breast Cancer Cells to TRAIL,” International Journal of Molecular Sciences 23, no. 24 (2022): 15551.

[292] E. R. Jackson, R. J. Duchatel, D. E. Staudt, et al., “ONC201 in Combination With Paxalisib for the Treatment of H3K27-Altere d Diffuse Midline Glioma,” Cancer Research 83, no. 14 (2023): OF1–OF17.

[293] D. de la Nava, I. Ausejo-Mauleon, V. Laspidea, et al., “The Oncolytic adenovirus Delta-24-RGD in Combination With ONC201 Induc es a Potent Antitumor Response in Pediatric High-grade and Diffuse Mid Line Glioma Models,” Neuro-Oncology 26, no. 8 (2024): 1509–1525.

[294] J. M. Przystal, C. Cianciolo Cosentino, S. Yadavilli, et al., “Imipridones Affect Tumor Bioenergetics and Promote Cell Lineage Differ Entiation in Diffuse Midline Gliomas,” Neuro-Oncology 24, no. 9 (2022): 1438–1451.

[295] S. Zhong, W. Chen, and B. Wang, “Energy Stress Modulation of AMPK/FoxO3 Signaling Inhibits Mitochondria -associated Ferroptosis,” Redox Biology 63 (2023): 102760.

[296] Y. Xia, C. Jia, Q. Xue, et al., “Antipsychotic Drug Trifluoperazine Suppresses Colorectal Cancer by Ind Ucing G0/G1 Arrest and Apoptosis,” Frontiers in Pharmacology 10 (2019): 1029.

[297] J. Y. Jeong, H. Park, H. Yoo, et al., “Trifluoperazine and Its Analog Suppressed the Tumorigenicity of Non-Sm All Cell Lung Cancer Cell; Applicability of Antipsychotic Drugs to Lun G Cancer Treatment,” Biomedicines 10, no. 5 (2022): 1046.

[298] C.-T. Yeh, A. T. H. Wu, P. M. H. Chang, et al., “Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Gro Wth and Overcomes Drug Resistance of Lung Cancer,” American Journal of Respiratory and Critical Care Medicine 186, no. 11 (2012): 1180–1188.

[299] Z. Feng, Y. Xia, T. Gao, et al., “The Antipsychotic Agent Trifluoperazine Hydrochloride Suppresses Tripl E-negative Breast Cancer Tumor Growth and Brain Metastasis by Inducing G0/G1 Arrest and Apoptosis,” Cell Death & Disease 9, no. 10 (2018): 1006.

[300] W. Shen, X. Zeng, X. Zeng, et al., “Trifluoperazine Activates AMPK /mTOR / ULK1 Signaling Pathway to Indu ce Mitophagy in Osteosarcoma Cells,” Chemico-Biological Interactions 392 (2024): 110904.

[301] P. D. Brown, V. Gondi, S. Pugh, et al., “Hippocampal Avoidance during Whole-Brain Radiotherapy plus Memantine f or Patients with Brain Metastases: Phase III Trial NRG Oncology CC001,” Journal of Clinical Oncology 38, no. 10 (2020): 1019–1029.

[302] P. D. Brown, S. Pugh, N. N. Laack, et al., “Memantine for the Prevention of Cognitive Dysfunction in Patients Rece Iving Whole-brain Radiotherapy: A Randomized, Double-blind, Placebo-co Ntrolled Trial,” Neuro-Oncology 15, no. 10 (2013): 1429–1437.

[303] D. Yuan, J. Hu, X. Ju, et al., “NMDAR Antagonists Suppress Tumor Progression by Regulating Tumor-assoc Iated Macrophages,” Proceedings of the National Academy of Sciences of the United States of America 120, no. 47 (2023): e2302126120.

[304] Z. M. Nakamura, A. M. Deal, E. M. Park, et al., “A Phase II Single-arm Trial of memantine for Prevention of Cognitive D Ecline During Chemotherapy in Patients With Early Breast Cancer: Feasi Bility, Tolerability, Acceptability, and Preliminary Effects,” Cancer Medicine 12, no. 7 (2023): 8172–8183.

[305] S. Seifabadi, G. Vaseghi, S. H. Javanmard, E. Omidi, M. Tajadini, and B. Zarrin, “The Cytotoxic Effect of Memantine and Its Effect on Cytoskeletal Prote Ins Expression in Metastatic Breast Cancer Cell Line,” Iranian Journal of Basic Medical Sciences 20, no. 1 (2017): 41–45.

[306] G. Albayrak and F. Demirtas Korkmaz, “Memantine Shifts Cancer Cell Metabolism via AMPK1/2 Mediated Energetic Switch in A549 Lung Cancer Cells,” EXCLI Journal 20 (2021): 223–231.

[307] G. L. Plosker and R. J. Milne, “Ondansetron: A Pharmacoeconomic and Quality-of-life Evaluation of Its Antiemetic Activity in Patients Receiving Cancer Chemotherapy,” Pharmacoeconomics 2, no. 4 (1992): 285–304.

[308] C. L. Dempsey, A. J. Coop, A. Shillington, P. A. Farley, D. R. Eberhardt, and S. O'Briant, “Antiemetic Effectiveness of Ondansetron and Granisetron in Patients wi th Breast Cancer Treated With Cyclophosphamide,” American Journal of Health-System Pharmacy 61, no. 8 (2004): 781–786.

[309] J. DiBenedetto, L. X. Cubeddu, T. Ryan, et al., “Ondansetron for Nausea and Vomiting Associated With Moderately Emetoge Nic Cancer Chemotherapy,” Clinical Therapeutics 17, no. 6 (1995): 1091–1098.

[310] G. Kovács, A. E. Wachtel, E. V. Basharova, T. Spinelli, P. Nicolas, and E. Kabickova, “Palonosetron versus ondansetron for Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Patients With Cancer Receiving Mode Rately or Highly Emetogenic Chemotherapy: A Randomised, Phase 3, Doubl E-blind, Double-dummy, Non-inferiority Study,” The Lancet Oncology 17, no. 3 (2016): 332–344.

[311] M. Levitt, D. Warr, L. Yelle, et al., “Ondansetron Compared With Dexamethasone and Metoclopramide as Antiemet Ics in the Chemotherapy of Breast Cancer With Cyclophosphamide, Methot Rexate, and Fluorouracil,” New England Journal of Medicine 328, no. 15 (1993): 1081–1084.

[312] K. S. Buser, R. A. Joss, D. Piquet, et al., “Oral Ondansetron in the Prophylaxis of Nausea and Vomiting Induced by Cyclophosphamide, Methotrexate and 5-fluorouracil (CMF) in Women With Breast Cancer. Results of a Prospective, Randomized, Double-blind, pla cebo-controlled Study,” Annals of Oncology: Official Journal of the European Society for Medical Oncology 4, no. 6 (1993): 475–479.

[313] P. Cheng, J. Wu, G. Zong, et al., “Capsaicin Shapes Gut Microbiota and Pre-metastatic Niche to Facilitate Cancer Metastasis to Liver,” Pharmacological Research 188 (2023): 106643.

[314] R. Deng, S. Yu, X. Ruan, et al., “Capsaicin Orchestrates Metastasis in Gastric Cancer via Modulating Exp Ression of TRPV1 Channels and Driving Gut Microbiota Disorder,” Cell Communication and Signaling 21, no. 1 (2023): 364.

[315] Z.-Y. Chen, H.-H. Huang, Q.-C. Li, et al., “Capsaicin Reduces Cancer Stemness and Inhibits Metastasis by Downregul Ating SOX2and EZH2in Osteosarcoma,” American Journal of Chinese Medicine 51, no. 4 (2023): 1041–1066.

[316] K.-C. Huang, Y.-F. Chiang, T.-C. Huang, et al., “Capsaicin Alleviates Cisplatin-induced Muscle Loss and Atrophy in Vitr o and in Vivo,” Journal of Cachexia, Sarcopenia and Muscle 14, no. 1 (2023): 182–197.

[317] C. Maihöfner, I. Diel, H. Tesch, T. Quandel, and R. Baron, “Chemotherapy-induced Peripheral Neuropathy (CIPN): Current Therapies a nd Topical Treatment Option With High-concentration Capsaicin,” Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 29, no. 8 (2021): 4223–4238.

[318] M. Sharan, M. Jha, R. Chandel, et al., “Demethylation of CADM1 and SOCS1 Using Capsaicin in Cervical Cancer ce Ll Line,” Naunyn-Schmiedebergs Archives of Pharmacology 396, no. 4 (2023): 649–657.

[319] M. Chen, C. Xiao, W. Jiang, et al., “Capsaicin Inhibits Proliferation and Induces Apoptosis in Breast Cance R by Down-Regulating FBI-1-Mediated NF-κB Pathway,” Drug Design, Development and Therapy 15 (2021): 125–140.

[320] T. Que, B. Ren, Y. Fan, et al., “Capsaicin Inhibits the Migration, Invasion and EMT of Renal Cancer Cel Ls by Inducing AMPK/mTOR-mediated Autophagy,” Chemico-Biological Interactions 366 (2022): 110043.

[321] S. Ravindranathan, T. Passang, J.-M. Li, et al., “Targeting Vasoactive Intestinal Peptide-mediated Signaling Enhances Response to Immune Checkpoint Therapy in Pancreatic Ductal Adenocarcinoma,” Nature Communications 13, no. 1 (2022): 6418.

[322] M. Calvani, G. Bruno, M. Dal Monte, et al., “beta(3) -Adrenoceptor as a Potential Immuno-suppressor Agent in Melanoma,” British Journal of Pharmacology 176, no. 14 (2019): 2509–2524.

[323] J. D. Violin, L. M. DiPilato, N. Yildirim, T. C. Elston, J. Zhang, and R. J. Lefkowitz, “beta2-adrenergic Receptor Signaling and Desensitization Elucidated by Quantitative Modeling of Real Time cAMP Dynamics,” Journal of Biological Chemistry 283, no. 5 (2008): 2949–2961.

[324] Z. Xie, X. Xu, W. Cao, et al., “Perspectives on miRNAs Directly Targeting BDNF for Cancer Diagnosis and Treatment (Review),” International Journal of Oncology 62, no. 2 (2023): 30.

[325] C. P. Le, C. J. Nowell, C. Kim-Fuchs, et al., “Chronic Stress in Mice Remodels Lymph Vasculature to Promote Tumour Cell Dissemination,” Nature Communications 7 (2016): 10634.

[326] Y. N. Kim, K. H. Koo, J. Y. Sung, U. J. Yun, and H. Kim, “Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis,” International Journal of Cell Biology 2012 (2012): 306879.

[327] S. Kumar, S. H. Park, B. Cieply, et al., “A Pathway for the Control of Anoikis Sensitivity by E-cadherin and Epithelial-to-mesenchymal Transition,” Molecular and Cellular Biology 31, no. 19 (2011): 4036–4051.

[328] E. Adriaenssens, E. Vanhecke, P. Saule, et al., “Nerve Growth Factor Is a Potential Therapeutic Target in Breast Cancer,” Cancer Research 68, no. 2 (2008): 346–351.

[329] M. C. Hochberg, J. A. Carrino, T. J. Schnitzer, et al., “Long-Term Safety and Efficacy of Subcutaneous Tanezumab versus Nonsteroidal Antiinflammatory Drugs for Hip or Knee Osteoarthritis: A Randomized Trial,” Arthritis & Rheumatology 73, no. 7 (2021): 1167–1177.

[330] Y. Zhang and Z. Zhang, “The History and Advances in Cancer Immunotherapy: Understanding the Characteristics of Tumor-infiltrating Immune Cells and Their Therapeutic Implications,” Cellular & Molecular Immunology 17, no. 8 (2020): 807–821.

[331] A. W. P. Jensen, A. M. Carnaz Simoes, P. Thor Straten, and G. Holmen Olofsson, “Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?,” Cancers (Basel) 13, no. 3 (2021): 394.

[332] K. Y. Fjaestad, A. M. A. Romer, V. Goitea, et al., “Blockade of Beta-adrenergic Receptors Reduces Cancer Growth and Enhances the Response to Anti-CTLA4 Therapy by Modulating the Tumor Microenvironment,” Oncogene 41, no. 9 (2022): 1364–1375.

[333] H. Greenlee, M. J. DuPont-Reyes, L. G. Balneaves, et al., “Clinical Practice Guidelines on the Evidence-based Use of Integrative Therapies During and After Breast Cancer Treatment,” CA: A Cancer Journal for Clinicians 67, no. 3 (2017): 194–232.

[334] K. Dhakal, C. Chen, P. Wang, J. F. Mboineki, and B. Adhikari, “Existing Psychological Supportive Care Interventions for Cervical Canc er Patients: A Systematic Review and Meta-analysis,” BMC Public Health [Electronic Resource] 24, no. 1 (2024): 1419.

[335] A. Wurz, E. McLaughlin, C. Lategan, K. Ellis, and S. N. Culos-Reed, “Synthesizing the Literature on Physical Activity Among Children and Ad Olescents Affected by Cancer: Evidence for the International Pediatric Oncology Exercise Guidelines (iPOEG),” Translational Behavioral Medicine 11, no. 3 (2021): 699–708.

[336] M. Caru, A. Levesque, S. Dandekar, and K. H. Schmitz, “Physical Activity and Psychological Support Can Replace “another Pill” to Manage Cancer-related Symptoms in Children and Adolescents Diagnos Ed With Cancer,” BMC Complementary Medicine and Therapies 24, no. 1 (2024): 170.

[337] C. Zhu, H. Ma, A. He, Y. Li, C. He, and Y. Xia, “Exercise in Cancer Prevention and Anticancer Therapy: Efficacy, Molecu Lar Mechanisms and Clinical Information,” Cancer Letters 544 (2022): 215814.

[338] Y.-F. Wang, Z.-Y. An, L.-Q. Yuan, T. Wang, and W.-L. Jin, “Lilium brownii/Baiheas Nutraceuticals: Insights Into It s Composition and Therapeutic Properties,” Pharmaceuticals (Basel, Switzerland) 17, no. 9 (2024): 1242.

[339] Q. Jia, Y. Zhou, L. Song, et al., “Baicalin Reduces Chronic Stress-induced Breast Cancer Metastasis via Directly Targeting beta2-adrenergic Receptor,” Journal of Pharmaceutical Analysis 14, no. 7 (2024): 100934.

[340] B. Williams, G. Mancia, W. Spiering, et al., “2018 ESC/ESH Guidelines for the Management of Arterial Hypertension,” European Heart Journal 39, no. 33 (2018): 3021–3104.

[341] G. Mancia, R. Kreutz, M. Brunstrom, et al., “2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA),” Journal of Hypertension 41, no. 12 (2023): 1874–2071.

[342] L. J. Philip, S. G. Findlay, and J. H. Gill, “Baseline Blood Pressure and Development of Cardiotoxicity in Patients Treated With Anthracyclines: A Systematic Review,” International Journal of Cardiology: Cardiovascular Risk and Prevention 15 (2022): 200153.

[343] D. Cardinale, A. Colombo, G. Bacchiani, et al., “Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy,” Circulation 131, no. 22 (2015): 1981–1988.

[344] H. K. Narayan, B. Finkelman, B. French, et al., “Detailed Echocardiographic Phenotyping in Breast Cancer Patients: Associations with Ejection Fraction Decline, Recovery, and Heart Failure Symptoms over 3 Years of Follow-Up,” Circulation 135, no. 15 (2017): 1397–1412.

[345] V. S. Hahn, D. J. Lenihan, and B. Ky, “Cancer Therapy-induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies,” Journal of the American Heart Association 3, no. 2 (2014): e000665.

[346] S. Bhatia, “Genetics of Anthracycline Cardiomyopathy in Cancer Survivors: JACC: CardioOncologyState-of-the-Art Review,” JACC: CardioOncology 2, no. 4 (2020): 539–552.

[347] T. Noma, A. Lemaire, S. V. Naga Prasad, et al., “Beta-arrestin-mediated beta1-adrenergic Receptor Transactivation of the EGFR Confers Cardioprotection,” Journal of Clinical Investigation 117, no. 9 (2007): 2445–2458.

[348] K. Lemmens, K. Doggen, and G. W. De Keulenaer, “Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure,” Circulation 116, no. 8 (2007): 954–960.

[349] C. Kotch, D. Barrett, and D. T. Teachey, “Tocilizumab for the Treatment of Chimeric Antigen Receptor T Cell-indu Ced Cytokine Release Syndrome,” Expert Review of Clinical Immunology 15, no. 8 (2019): 813–822.

[350] M. A. Jordan and L. Wilson, “Microtubules as a Target for Anticancer Drugs,” Nature Reviews Cancer 4, no. 4 (2004): 253–265.

[351] M. R. Mulvey, C. A. Paley, A. Schuberth, N. King, A. Page, and K. Neoh, “Neuropathic Pain in Cancer: What Are the Current Guidelines?,” Current Treatment Options in Oncology 25, no. 9 (2024): 1193–1202.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.